


RESEARCH

Open Access



# Age-dependent dopamine transporter dysfunction and Serine129 phospho- $\alpha$ -synuclein overload in G2019S LRRK2 mice

Francesco Longo<sup>1†</sup>, Daniela Mercatelli<sup>1†</sup>, Salvatore Novello<sup>1</sup>, Ludovico Arcuri<sup>1</sup>, Alberto Brugnoli<sup>1</sup>, Fabrizio Vincenzi<sup>1</sup>, Isabella Russo<sup>2</sup>, Giulia Berti<sup>2</sup>, Omar S. Mabrouk<sup>3</sup>, Robert T. Kennedy<sup>3</sup>, Derya R. Shimshek<sup>4</sup>, Katia Varani<sup>1</sup>, Luigi Bubacco<sup>2</sup>, Elisa Greggio<sup>2</sup> and Michele Morari<sup>1\*</sup> 

## Abstract

Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most common genetic cause of Parkinson's disease. Here, we investigated whether the G2019S LRRK2 mutation causes morphological and/or functional changes at nigro-striatal dopamine neurons. Density of striatal dopaminergic terminals, nigral cell counts, tyrosine hydroxylase protein levels as well as exocytotic dopamine release measured in striatal synaptosomes, or striatal extracellular dopamine levels monitored by in vivo microdialysis were similar between  $\geq 12$ -month-old G2019S knock-in mice and wild-type controls. In vivo striatal dopamine release was insensitive to the LRRK2 inhibitor Nov-LRRK2-11, and was elevated by the membrane dopamine transporter blocker GBR-12783. However, G2019S knock-in mice showed a blunted neurochemical and motor activation response to GBR-12783 compared to wild-type controls. Western blot and dopamine uptake analysis revealed an increase in dopamine transporter levels and activity in the striatum of 12-month-old G2019S KI mice. This phenotype correlated with a reduction in vesicular monoamine transporter 2 levels and an enhancement of vesicular dopamine uptake, which was consistent with greater resistance to reserpine-induced hypolocomotion. These changes were not observed in 3-month-old mice. Finally, Western blot analysis revealed no genotype difference in striatal levels of endogenous  $\alpha$ -synuclein or  $\alpha$ -synuclein bound to DOPAL (a toxic metabolite of dopamine). However, Serine129-phosphorylated  $\alpha$ -synuclein levels were higher in 12-month-old G2019S knock-in mice. Immunohistochemistry confirmed this finding, also showing no genotype difference in 3-month-old mice. We conclude that the G2019S mutation causes progressive dysfunctions of dopamine transporters, along with Serine129-phosphorylated  $\alpha$ -synuclein overload, at striatal dopaminergic terminals, which are not associated with dopamine homeostasis dysregulation or neuron loss but might contribute to intrinsic dopaminergic terminal vulnerability. We propose G2019S knock-in mice as a presymptomatic Parkinson's disease model, useful to investigate the pathogenic interaction among genetics, aging, and internal or environmental factors leading to the disease.

**Keywords:**  $\alpha$ -synuclein, DAT, G2019S knock-in, LRRK2, Parkinson's disease, VMAT2

\* Correspondence: m.morari@unife.it

<sup>†</sup>Equal contributors

<sup>1</sup>Department of Medical Sciences, Section of Pharmacology, and National Institute of Neuroscience, University of Ferrara, via Fossato di Mortara 17-19, 44121 Ferrara, Italy

Full list of author information is available at the end of the article



## Introduction

Autosomal-dominant missense mutations in the leucine-rich repeat kinase 2 (*LRRK2*) gene (PARK8, OMIM 609007) cause familial late-onset Parkinson's disease (PD) [59, 95]. *LRRK2* mutations also occur in 1–2% of sporadic cases [28, 70] and recent genome wide association studies (GWAS) showed that common variations in the *LRRK2* locus increase the risk of disease, pointing to a crucial role of *LRRK2* in the pathogenesis of PD. *LRRK2*-associated PD is clinically and pathologically indistinguishable from the idiopathic form [18], although some differences in motor and non-motor features have been reported [46]. The majority of *LRRK2* autopsied cases report progressive degeneration of dopamine (DA) neurons located in the substantia nigra pars compacta (SNpc), and  $\alpha$ -synuclein ( $\alpha$ -syn)/ubiquitin-positive intraneuronal cytoplasmic inclusions in surviving neurons [31, 33], although a pleomorphic pathology associated with other neurodegenerative diseases has also been observed [95]. Despite the undisputed genetic link between *LRRK2* mutations and PD, the pathogenic mechanisms through which *LRRK2* mutations affect PD onset and progression remain debated [17, 49]. *LRRK2* is a complex multi-domain protein belonging to the ROCO family, characterized by the presence of a GTPase and a serine-threonine kinase domain surrounded by a number of protein-protein interaction domains [16, 51]. The most common *LRRK2* pathogenic mutations are represented by Gly2019-Ser (G2019S) in the kinase domain, followed by the hot-spot mutation Arg1441Cys/Gly/His/Ser (R1441C/G/H/S) in the GTPase domain [19, 73]. The G2019S mutation results in a two to threefold increase in *LRRK2* kinase activity, which appears to be crucial for *LRRK2*-induced neurodegeneration in vitro [26, 90, 91]. More recently, the cellular activity of *LRRK2*, probed with anti-autophosphorylation antibodies against Serine 1292 [67, 72] and by measuring the phosphorylation of a subset of Rab GTPase which are *bona fide* *LRRK2* cellular substrates [76], revealed a homogeneous increase of *LRRK2* kinase activity in the presence of pathogenic mutations, which is not limited to the G2019S mutant as it occurs in vitro.

Various *LRRK2* rodent models have been generated in the attempt to replicate the dysfunction and/or degeneration of the nigro-striatal dopaminergic pathway in vivo. Unfortunately, these models provided conflicting data. Mice overexpressing human G2019S or R1441C/G mutations through BAC technology did not show overt dopaminergic neurodegeneration [39, 40, 53] but reduced striatal DA content or basal extracellular levels in vivo when compared to non-transgenic wild-type controls [4, 53]. Consistently, the  $K^+$ -evoked DA release was reduced in striatal slices from BAC hG2019S mice [40]. In mice where hG2019S [13, 64] or hR1441C [88]

overexpression in SNc was achieved through the CMV/PDGF promoter, an 18–50% reduction in the number of nigral DA cells was observed at old ages (16–21 months). In these mice, no changes of in vivo DA content was observed [64], although the  $K^+$ -evoked DA release from striatal slices was reduced [88]. Conditional expression of hG2019S [41] or hR1441C [83] in SNc also did not cause nigral DA neuron loss; only a mild reduction in the density of TH terminals was observed in 16-month-old mice [41]. In these mice, hG2019S overexpression caused a reduction of DA content and release from striatal slices [41]. Lack of nigro-striatal degeneration [37, 74, 93] or changes in DA content [37, 93] were also confirmed in transgenic rats overexpressing hG2019S or hR1441C mutations. In vitro, a reduction of the  $K^+$ -evoked DA release in BAC overexpressing rats was found [74]. Finally, no overt neurodegeneration [29, 82, 92] or changes in striatal DA content [29, 82] were observed in G2019S or R1441C knock-in (KI) mice, although in vivo microdialysis revealed a 60% reduction in both spontaneous and amphetamine-induced DA release in 12-month-old G2019S KI mice [92].

In a previous longitudinal study, we reported that G2019S KI mice had enhanced motor behavior compared to both WT mice and mice carrying the D1994S kinase-dead mutation [43]. In this follow-up study, we sought to investigate the mechanisms underlying such phenotype, and in particular, whether G2019S *LRRK2* is associated with dysregulation of nigro-striatal DA transmission. Indeed, in vivo [93] and in vitro [54] evidence that the G2019S mutation can be associated with increased DA release has been presented. Here, different aspects of striatal DA transmission were evaluated, namely the integrity of the nigro-striatal DA pathway, in vivo and in vitro striatal DA release, expression and function of proteins involved in synaptic load (DA transporter, DAT) or vesicle storage (vesicular monoamine transporter type 2; VMAT2) of DA, and, finally, the levels of endogenous  $\alpha$ -syn, and its Serine129 phosphorylated (pSer129  $\alpha$ -syn) or 3,4-dihydroxyphenylacetaldehyde (DOPAL)-bound forms, which are considered markers of synaptic damage.

## Materials and methods

### Animals

Male homozygous *LRRK2* G2019S KI mice, backcrossed on a C57Bl/6 J background, were used. Mice were obtained from Novartis Institutes for BioMedical Research, Novartis Pharma AG (Basel, Switzerland) [29], and bred in the vivarium of the University of Ferrara. In behavioral and neurochemical studies, male non-transgenic wild-type (WT) mice were littermates obtained from the heterozygous breeding. Otherwise, WT mice were obtained from homozygous breeding. Mice were kept

under regular lighting conditions (12 h light/dark cycle) and given food and water ad libitum. Experimental procedures involving the use of animals were approved by the Ethical Committee of the University of Ferrara and the Italian Ministry of Health (licenses 171/2010-B and 318/2013-B). Adequate measures were taken to minimize animal pain and discomfort.

### Behavioral pharmacology

Three behavioral tests specific for different motor abilities, i.e. the bar, drag and rotarod tests, were used as described [43, 84, 85]. Experimenters were unaware of genotype and treatments. Twelve-month-old mice were acutely administered i.p. with the VMAT2 inhibitor reserpine at the doses of 1 or 2 mg/kg [87], or with the DAT inhibitor GBR-12783 at the dose of 6 mg/kg.

The bar test measures the ability of the animal to respond to an externally imposed static posture. Mice were gently placed on a table and forepaws were placed alternatively on blocks of increasing heights (1.5, 3 and 6 cm). The time (in seconds) that each paw spent on the block (i.e. the immobility time) was recorded (cut-off time of 20 s). Performance was expressed as total time spent on the different blocks. The drag test measures the ability of the animal to balance its body posture with the forelimbs in response to an externally imposed dynamic stimulus (backward dragging) [47]. It gives information regarding the time to initiate and execute (bradykinesia) a movement. Animals were gently lifted from the tail leaving the forepaws on the table, and then dragged backwards at a constant speed (about 20 cm/s) for a fixed distance (100 cm). The number of steps made by each paw was recorded. Five to seven determinations were collected for each animal. Finally, the fixed-speed rotarod test integrates different motor parameters such as motor coordination, gait ability, balance, muscle tone and motivation to run. Mice were tested over a wide range of increasing speeds (0–55 rpm; 5 rpm steps, increased every 180 s) on a rotating rod (diameter of the cylinder 8 cm) and the total time spent on the rod was recorded [84, 85]

### In vivo microdialysis

Two concentric microdialysis probes (1 mm Cuprophane membrane with a 6 kDa cut-off; AgnTho's, Stockholm, Sweden) were stereotaxically implanted under isoflurane anesthesia in both dorsal striata (coordinates from the bregma: AP +0.6, ML  $\pm$ 2.0, DV -2.0) [62]. Twenty-four hours after implantation, probes were perfused (2.1  $\mu$ l/min) with a modified Ringer solution (in mM CaCl<sub>2</sub> 1.2; KCl 2.7; NaCl 148 and MgCl<sub>2</sub> 0.85) and samples were collected every 20 min [6, 45, 87] after a 6 h wash-out period. Experiments were run at 24 and 48 h after implantation, and treatments were randomized. GBR-

12783 and Nov-LRRK2-11 were administered at 20 mg/kg (i.p.) and 10 mg/kg (i.p.), respectively.

### Neurochemical analysis using LC-MS

DA, HVA, DOPAC and 3MT concentrations in dialysates were analyzed using a benzylation derivatization LC-MS method described by [75]. Briefly, 5  $\mu$ l dialysate samples were derivatized by adding 2.5  $\mu$ l of 100 mM sodium tetraborate, 2.5  $\mu$ l of 2% benzoyl chloride in acetonitrile, and 2.5  $\mu$ l of a stable <sup>13</sup>C benzoylated isotope internal standard mixture for improved quantitation. A Thermo Fisher Accela UHPLC (Waltham, MA) system automatically injected 5  $\mu$ l of the sample onto a Waters (Milford, MA) HSS T3 reverse phase HPLC column (1 mm X 100 mm, 1.8  $\mu$ m). Mobile phase A consisted of 10 mM ammonium formate and 0.15% formic acid. Mobile phase B was pure acetonitrile. Analytes were detected by a Thermo Fisher TSQ Quantum Ultra triple quadrupole mass spectrometer operating in multiple reaction monitoring (MRM) mode. Run times were approximately 6 min and all analytes could be detected well above quantification limits (data not shown).

### Synaptosomes preparation

Mice were anesthetized and decapitated. Striata from each mouse were homogenized in ice-cold 0.32 M sucrose (pH 7.4) with a Teflon-glass homogenizer and centrifuged at 9,500 g for 10 min at 4 °C. The supernatant was then centrifuged at 10,000 g for 20 min at 4 °C, and the pellet processed for (i) release experiments or (ii) DA uptake assay.

### Release experiments

The pellet was resuspended in 1.5 ml of pre-oxygenated Krebs solution (in mM: NaCl 118.5, KCl 4.7, CaCl<sub>2</sub> 1.2, MgSO<sub>4</sub> 1.2, KH<sub>2</sub>PO<sub>4</sub> 1.2, NaHCO<sub>3</sub> 25, glucose 10, ascorbic acid 0.05, disodium EDTA 0.03, pH 7.4) and incubated with 50 nM [<sup>3</sup>H]-DA (specific activity 40 Ci/mmol; Perkin-Elmer, Boston, MA, USA) for 25 min at 36.5 °C [48]. At the end of the incubation, 12 ml of pre-oxygenated Krebs were added, then 1 ml aliquots of the suspension (~0.35 mg protein) were injected into nylon syringe filters maintained at 36.5 °C and superfused (0.4 ml/min) with pre-oxygenated Krebs. Under these superfusion conditions, spontaneous [<sup>3</sup>H]-DA efflux is essentially unaffected by reuptake [48]. Sample collection (every 3 min) was initiated after a 20 min period of filter washout. Radioactivity in the samples and in the filters was measured using a Perkin Elmer Tri Carb 2810 TR scintillation counter.

### DA uptake assay

The pellet was resuspended in ice-cold uptake buffer (in mM: NaCl 125, KCl 5, MgSO<sub>4</sub> 1.5, CaCl<sub>2</sub> 1.2, KH<sub>2</sub>PO<sub>4</sub>

1.5, glucose 10, HEPES 25, pargyline 0.1, ascorbic acid 0.5, pH 7.4) and incubated for 5 min at 37 °C with 20 nM [<sup>3</sup>H]-DA isotopically diluted with varying concentrations of unlabeled DA to obtain final DA concentrations in the 20–2000 nM range. Non-specific DA uptake was evaluated in the presence of 5 μM GBR-12783. The reaction was terminated by filtering the assay mixture through Whatman GF/B glass fiber filters using a Brandel cell harvester (Brandel Instruments, Unterföhring, Germany). The filter-bound radioactivity was counted using a Perkin Elmer Tri Carb 2810 TR scintillation counter. Specific DA uptake, defined as the difference between DA accumulated in the absence and in the presence of GBR-12783, was expressed as pmol/mg protein/min [94]. Protein concentration was determined using a Bio-Rad method with bovine albumin as standard reference. Kinetic parameters ( $V_{max}$  and  $K_m$ ) were determined using Prism 5.0 (GraphPad Software Inc., San Diego, CA).

#### Western blot analysis

Mice were anesthetized and decapitated. Striata were solubilized and homogenized in lysis buffer (RIPA buffer, protease and phosphatase inhibitor cocktail) and centrifuged at 13,000 rpm for 15 min at 4 °C. Supernatants were collected and total protein levels were quantified using the bicinchoninic acid protein assay kit (Thermo Scientific). Thirty micrograms of protein per sample were separated by SDS-PAGE, transferred onto polyvinylidene difluoride membrane and tested for the following primary antibodies: rabbit anti-tyrosine hydroxylase (TH) (Merck Millipore, AB152, 1:1000), rabbit anti-DAT (Sigma Aldrich, D6944, 1:1000), rabbit anti-VMAT2 (Sigma Aldrich, V9014, 1:300), rabbit anti-VMAT2 (Miller Lab, Emory University, 1:1000 [15]), rabbit anti-pSer129 α-syn (Abcam, ab51253, 1:1000), rabbit anti-pSer1292 LRRK2 (Abcam, ab203181, 1:300). Appropriate horseradish peroxidase-linked secondary antibodies (Merck Millipore, goat anti-rabbit IgG HRP-conjugate 12–348, 1:4000 or goat anti-rat IgG HRP-conjugate AP136P, 1:5000) were then used and immunoreactive proteins were visualized by enhanced chemiluminescence (ECL) detection kit (Pierce™ BCA Protein Assay Kit, Thermo Scientific or ECL+, GE Healthcare). Images were acquired and quantified using the ChemiDoc MP System and the ImageLab Software (Bio-Rad). Membranes were then stripped and re-probed with rabbit anti-GAPDH antibody (Thermo Scientific, PA1-988, 1:1000), rabbit anti-LRRK2 (Abcam, ab133474, 1:300) or rabbit anti-α-syn antibody (Abcam, ab52168, 1:1000). Data were analyzed by densitometry and the optical density of specific target protein bands was normalized to the corresponding housekeeper protein levels.

DOPAL-bound α-syn was revealed using ABPA resin (Sigma Aldrich, A8530) pulldown [35, 66]. Five-hundred

micrograms total protein were incubated with 50 μl of the resin overnight at 4 °C shaking. The resin was then pelleted, the supernatant removed and the resin was washed twice with PBS/acetonitrile and water. Protein was collected from the resin by adding 20 μl Laemmli buffer and processed as described above using the anti-α-syn antibody. The band intensity was quantified by Image J software and the pull down protein was compared with the total lysate.

#### Immunohistochemistry

Mice were deeply anesthetized with isoflurane and transcardially perfused with 4% paraformaldehyde in Phosphate Buffer Solution (PBS; 0.1 M, pH 7.4). Brains were removed, transferred to a 30% sucrose solution in PBS for cryoprotection and then stored at –80 °C.

#### TH, α-syn and pSer129 α-syn immunohistochemistry

Fifty micrometer free-floating sections of striatum (AP from +1.42 to +0.14 from bregma) and SNc (AP from –3.16 to –3.52 from bregma [62]) were rinsed in PBS incubated for 30 min at room temperature with a blocking solution (PBS + BSA 1:50 + Triton X100 0.3%) and then incubated with a rabbit polyclonal antibody raised against TH (ab112; 1:750 in BSA 1% PBST; Abcam, Cambridge, UK), α-syn (ab52168; 1:250 in BSA 1% PBST; Abcam, Cambridge, UK) or pSer129 α-syn (ab52153; 1:200 in BSA 1% PBST; Abcam, Cambridge, UK) overnight at 4 °C. Sections were then rinsed and incubated with an anti-rabbit HRP-conjugated secondary antibody (ab6721, 1:500 in BSA 1% PBST; Abcam, Cambridge UK) and revealed by a DAB substrate kit (ab64238, Abcam, Cambridge, UK). Sections were mounted on gelatinized slides, dehydrated and coverslipped for further analysis. To quantify the levels of expression of α-syn and pSer129 α-syn, the semi-stereological method described by Bourdenx et al. [7] was employed. This method has been rigorously standardized; in fact all serial striatal slices for each animal were taken, marked, put in the same well and exposed to DAB for 1 min (according to the data sheet of Abcam DAB substrate Kit). After being mounted, slides were scanned and the representative surface of the staining in each SN section was determined using a color threshold, then the area was sampled (probes of 50 × 40 μm, space 150 × 120 μm). The Cavalieri principle was applied to evaluate the representative volume of α-syn or pSer129 α-syn expression for each SN. The SN volume obtained from the α-syn staining was used to calculate the pSer129 α-syn expression as a percentage, thus allowing the comparison between the two different groups.

### Stereology and neuron counting

Stereological analysis was performed counting TH+ neurons (phenotypic marker) and cresyl violet stained cells (structural marker) in SNc, according to an unbiased stereological sampling method based on optical fractionator stereological probe [34]. A Leica DM6000B motorized microscope coupled with the Mercator Pro software (Mercator Digital Imaging System, Explora Nova, La Rochelle, France) was used [2, 5, 7]. Counting was performed on at least 5 consecutive 50  $\mu\text{m}$  thick slices, magnified at 40X.

### VMAT2 activity assay

Mice were anesthetized and decapitated. Whole brains were homogenized in ice-cold buffer (4 mM HEPES, 0.32 M sucrose, pH 7.4) and centrifuged at 1,000 g for 10 min at 4 °C [10]. Supernatants were centrifuged at 20,000 g for 20 min at 4 °C, the resulting pellets were resuspended in 1.6 ml of resuspension buffer (0.32 M sucrose, pH 7.4) and subjected to osmotic shock by 10 up-and-down strokes in 6.4 ml of ice-cold water followed by addition of 1 ml of 250 mM HEPES and 1 M potassium tartrate, pH 7.4, to restore osmolarity. Samples were then centrifuged at 20,000 g for 20 min at 4 °C, and supernatants were centrifuged at 120,000 g for 2 h at 4 °C. Final pellets containing synaptic vesicles were resuspended in assay buffer (100 mM potassium tartrate, 25 mM HEPES, 0.1 mM EDTA, 0.05 mM EGTA, 1.7 mM ascorbate, 2 mM ATP disodium salt, pH 7.4) and incubated for 5 min at 37 °C with 20 nM [ $^3\text{H}$ ]-DA isotopically diluted with varying concentrations of unlabeled DA. Non-specific DA uptake was evaluated in the presence of 10  $\mu\text{M}$  tetrabenazine. The reaction was terminated by filtering the assay mixture through 0.5% polyethylenamine-soaked Whatman GF/B glass fiber filters using a Brandel cell harvester. The filter-bound radioactivity was counted using a Perkin Elmer Tri Carb 2810 TR scintillation counter.

### Data presentation and statistical analysis

Data are expressed as percentage of baseline (behavioral experiments) or absolute values and are mean  $\pm$  SEM (standard error of the mean) of  $n$  mice. Statistical analysis of drug effect was performed by one-way conventional or repeated measure (RM) analysis of variance (ANOVA) followed by the Newman-Keuls test for multiple comparisons, or by two-way ANOVA followed by Bonferroni test for multiple comparisons. The Student  $t$ -test, two tailed for unpaired data, was used to compare two groups of data.  $P$ -values  $<0.05$  were considered to be statistically significant.

### Drugs

GBR-12783 dihydrochloride and reserpine were purchased from Tocris Bioscience (Bristol, UK). Nov-LRRK2-11 was obtained from Novartis Institutes for BioMedical Research, Novartis Pharma AG (Basel, Switzerland).

### Results


#### The nigro-striatal DA pathway is intact in G2019S KI mice

To confirm that the G2019S KI mice under study possess enhanced LRRK2 kinase activity, we monitored LRRK2 autophosphorylation levels at Ser1292 using Western blotting. We found that pSer1292 levels were  $\sim 8$ -fold higher in the striatum of 12-month-old G2019S KI mice compared to age-matched WT littermates (Fig. 1), indicating a clear-cut gain of kinase activity in the presence of the G2019S mutation.

We next investigated the possibility that the G2019S mutation compromises the integrity of nigro-striatal DA neurons (Fig. 2). No differences in nigral DA cell number or density of striatal TH-positive terminals were detected between 12-month-old (Fig. 2a and b, respectively) or 19-month-old (data not shown) G2019S KI and WT mice. Likewise, striatal TH levels were similar between genotypes in 12-month-old animals (Fig. 2c).

#### Striatal DA release is preserved in G2019S KI mice

To investigate whether the exocytotic properties of DA terminals were affected by the G2019S mutation (Fig. 3), synaptosomes obtained from the striatum of 12-month-old mice were depolarized with a sequence of three 90-s pulses (18 min away) of 10 mM or 20 mM  $\text{K}^+$  (Fig. 3a). No differences in spontaneous [ $^3\text{H}$ ]-DA efflux (Fig. 3a) and  $\text{K}^+$ -evoked [ $^3\text{H}$ ]-DA overflow (Fig. 3a,b) were observed between G2019S KI mice and aged-matched WT controls, both after a single or repeated pulses, suggesting that enhanced LRRK2 kinase activity is not associated with changes of striatal DA release. Consistently, *in vivo* microdialysis revealed no significant differences in dialysate levels of DA and DA metabolites (DOPAC, HVA and 3-MT) between 19-month-old G2019S KI mice and WT littermates (Table 1), although a trend for higher DA and lower metabolites levels in G2019S KI mice was observed. Indeed, significant reductions of HVA/DA and 3-MT/DA ratios in G2019S KI mice were found, the reduction of DOPAC/DA ratio being close to significance ( $p = 0.067$ ; Table 1), suggesting a slower DA metabolism in G2019S KI mice. Microdialysis also revealed that the LRRK2 kinase inhibitor Nov-LRRK2-11 (10 mg/kg, *i.p.*), which normalizes motor performance in G2019S KI mice [43], did not affect striatal DA release in any genotypes (Fig. 4a), suggesting the motor phenotype of G2019S KI mice did not rely on greater DA release.




**Fig. 1** Phosphorylation levels of LRRK2 at Ser1292 (pSer1292) are elevated in G2019S knock-in (KI) mice. Striatal pSer1292 and total LRRK2 levels were measured by Western blotting in 12-month-old G2019S KI mice and age-matched WT controls. Representative blots (left) and quantification (right) are shown. Data are expressed as pSer1292 LRRK2/total LRRK2 and are means  $\pm$  SEM of 7 animals per group. Statistical analysis was performed with the Student *t*-test, two tailed for unpaired data. \*\**p* < 0.01, different from WT

**Age-dependent dysfunction of DAT in G2019S KI mice**


Since extracellular DA levels strongly rely on DAT activity, we investigated whether the trend for an increase in extracellular DA levels observed in G2019S KI mice was associated with changes in DAT activity. Microdialysis showed that striatal DA levels were elevated in both genotypes after administration of the DAT blocker GBR-12783 (20 mg/Kg, i.p) (Fig. 4b). However, the response in WT mice was more rapid and larger (maximum ~3-

fold over basal) compared to that in G2019S KI mice that was delayed and blunted (~2-fold over basal) (Fig. 4b).

To confirm dysfunctional DAT activity, we monitored motor performances following GBR-12783 administration. As previously reported [43], G2019S KI mice were more active (*p* < 0.001) in the bar and drag tests ( $18.29 \pm 1.62$  s and  $13.67 \pm 0.47$  steps, respectively; *n* = 60) compared to WT littermates ( $31.57 \pm 1.65$  s and  $9.92 \pm 0.39$



**Fig. 2** The integrity of nigro-striatal dopaminergic neurons is preserved in G2019S knock-in (KI) mice. Stereological count of nigral DA neurons (a) and density of tyrosine hydroxylase (TH) positive striatal nerve terminals (b), with representative images, in 12-month-old G2019S KI mice and age-matched WT littermates. Western blotting analysis of striatal TH levels in 12-month-old G2019S KI mice and age-matched WT controls (c). Data are expressed as absolute values and are means  $\pm$  SEM of 8 (a-b) and 4 (c) animals per group



steps, respectively;  $n = 58$ ). Conversely, rotarod performance was similar in G2019S KI and WT mice ( $837.58 \pm 21.73$  and  $872.2 \pm 31.89$  s, respectively). GBR-12783 (6 mg/Kg) reduced the immobility time (Fig. 4c) and increased the stepping activity (Fig. 4d) in WT but not G2019S KI mice, while causing a delayed increase in rotarod performance in both genotypes (Fig. 4e).

We then investigated DAT expression and function in striatal synaptosomes from 12-month-old mice (Fig. 5a, b). Analysis of DA uptake kinetics (Fig. 5a) revealed a significant 63% increase of maximal transport rate ( $V_{\text{max}}$ ) in striatal synaptosomes from G2019S KI mice ( $33.1 \pm 1.4$  pmol/mg prot/min) with respect to

WT mice ( $20.2 \pm 1.1$  pmol/mg prot/min;  $p < 0.01$ ), without changes in the DA affinity for the transporter ( $K_m$   $76.3 \pm 8.5$  nM vs  $67.9 \pm 9.0$  nM in G2019S KI and WT mice, respectively). Consistent with higher  $V_{\text{max}}$ , Western blot analysis showed that DAT protein levels were  $\sim 4$ -fold higher in G2019S KI than WT mice (Fig. 5b). To investigate whether these changes were age-dependent, experiments were replicated in younger animals (Fig. 5c,d). No differences were observed in  $[^3\text{H}]\text{-DA}$  uptake kinetics between 3-month-old G2019S KI mice ( $K_m$   $66.2 \pm 10.1$  nM,  $V_{\text{max}}$   $26.5 \pm 1.7$  nM) and age-matched WT controls ( $K_m$   $70.5 \pm 10.6$  nM,  $V_{\text{max}}$   $25.3 \pm 0.6$  nM) (Fig. 5c). Likewise, protein levels were similar between genotypes at this age (Fig. 5d).

#### Age-dependent dysfunction of VMAT2 in G2019S KI mice


Since the DAT/VMAT2 ratio is a vulnerability factor in DA neurons [56], we next investigated whether VMAT2 was also dysfunctional in G2019S KI mice (Fig. 6). First, the VMAT2 blocker reserpine was administered (1 mg/Kg, i.p.) to 12-month-old mice (Fig. 6a-c). G2019S KI and WT mice showed similar increases of immobility time 24 h after reserpine administration, although G2019S KI mice were also affected at 48 h (Fig. 6a). Conversely, reserpine reduced stepping activity (Fig. 6b) and rotarod performance (Fig. 6c) selectively in WT mice, both at 24 h and 48 h after administration. Higher reserpine doses (2 mg/Kg), however, caused similar motor impairments in both genotypes (data not shown). We then measured VMAT2 uptake activity in a preparation of whole-brain synaptic vesicles (Fig. 6d). VMAT2 affinity for DA ( $K_m$ ) was similar between 12-month-old G2019S KI mice and WT controls ( $356.3 \pm 25.2$  vs  $333.6 \pm 31.0$  nM, respectively), although  $V_{\text{max}}$  was significantly higher in G2019S KI mice ( $52.7 \pm 2.4$  vs  $43.2 \pm 2.2$  nM, respectively;  $p < 0.05$ ). Striatal VMAT2 protein levels were then analyzed, comparing a commercially available (Fig. 6e) with an in-house validated [15] antibody (Fig. 6f). Both antibodies revealed a  $\sim 50\%$  reduction of VMAT2 levels in G2019S KI mice. Finally, VMAT2 activity and protein levels were measured in 3-month-old mice (Fig. 6g-i). As for DAT, no differences between genotypes were observed at this age.

**Table 1** Basal dialysate levels (nM) of DA and its metabolites DOPAC, 3-MT and HVA monitored using in vivo microdialysis in the dorsal striatum of 19-month-old G2019S knock-in mice (G2019S KI) and wild-type littermates (WT)

genotype		DA	DOPAC	HVA	3-MT	DOPAC/DA	HVA/DA	3-MT/DA
WT	nM	$0.28 \pm 0.06$	$47.31 \pm 15.98$	$82.39 \pm 21.44$	$0.99 \pm 0.51$	$247.63 \pm 112.25$	$242.30 \pm 36.65$	$2.96 \pm 0.87$
G2019S KI	nM	$0.36 \pm 0.06$	$22.12 \pm 5.63$	$54.74 \pm 11.63$	$0.42 \pm 0.082$	$48.65 \pm 10.39$	$114.00 \pm 36.50^*$	$1.14 \pm 0.24^*$

\* $p < 0.05$ , significantly different from WT

The metabolite/DA ratios are also reported. Data are means  $\pm$  SEM of 11–15 determinations per group and were analyzed using the Student *t*-test, two-tailed for unpaired data



#### Age-dependent increase of pSer129 $\alpha$ -syn in G2019S KI mice


An increase of DAT activity [50] can lead to an increased cytosolic DA levels and buildup of byproducts of DA metabolism which are toxic for the cell. Among these, DOPAL [8, 52, 60], which is known to covalently bind to  $\alpha$ -syn at lysine residues [21, 89]. We therefore measured DOPAL-bound  $\alpha$ -syn levels in the striatum of 12-month-old G2019S KI mice compared to WT controls (Fig. 7a). No significant difference between genotypes was found. We then investigated pSer129  $\alpha$ -syn levels (Fig. 7b, c), since this posttranslational modification of  $\alpha$ -syn is thought to influence  $\alpha$ -syn aggregation and is highly represented in intracellular inclusions and Lewy Bodies [1, 24, 69]. Total endogenous  $\alpha$ -syn levels were not different between genotypes (Fig. 7b) whereas pSer129  $\alpha$ -syn levels were  $\sim$ 2-fold higher in the striatum of G2019S KI mice (Fig. 7c). To study the localization of  $\alpha$ -syn and pSer129  $\alpha$ -syn, immunohistochemistry was

employed in striatal slices from 12-month-old mice (Fig. 8).  $\alpha$ -syn and pSer129  $\alpha$ -syn inclusions were revealed in striatal neurons of both genotypes, seemingly at the cell body level. Endogenous  $\alpha$ -syn levels did not differ between genotypes (Fig. 8a), while pSer129  $\alpha$ -syn inclusions were significantly higher in the striatum of G2019S KI mice compared to WT controls (Fig. 8b). We next confirmed that such increase was age-dependent, since no difference in striatal  $\alpha$ -syn or pSer129  $\alpha$ -syn levels was observed between 3-month-old G2019S KI mice and WT controls (Fig. 8c, d).

#### Discussion

We previously reported that G2019S KI mice have a hyperkinetic phenotype relying on elevated kinase activity [43]. In this follow-up, we show that 12-month-old G2019S KI and WT mice bear similar numbers of nigral DA neurons and striatal DA terminals, in keeping with previous studies in the same genotype [29, 92] or in






**Fig. 5** Age-dependent dysfunction of DAT expression and function in G2019S knock-in (KI) mice. Kinetic analysis of [<sup>3</sup>H]-DA uptake in synaptosomes (a, c), and Western blotting analysis of DAT protein levels (and representative blots) (b, d) were performed in the striata of 12-month-old (a, b) and 3-month-old (c, d) G2019S KI mice in comparison with age-matched WT controls. Values are expressed as mean ± SEM of n = 4 (uptake) or n = 3 (Western blotting) independent experiments performed in duplicate. Statistical analysis was performed using the Student *t*-test, two-tailed for unpaired data. \**p* < 0.05, different from WT

BAC G2019S overexpressing mice [40, 53] and rats [37, 74, 93], as well as similar extracellular DA levels and depolarization-evoked striatal DA release, in line with that found in 22-month old R1441G KI mice [82]. Since the LRRK2 kinase inhibitor Nov-LRRK2-11 [43] also failed to affect striatal DA release in vivo in any genotypes, we conclude that the nigro-striatal DA system is morphologically intact and the exocytotic properties of DA neurons are functionally preserved in G2019S LRRK2 carriers.

The lack of changes of striatal DA release is at striking variance with the 60% reduction in basal striatal extracellular DA levels reported, in the absence of motor phenotype change, in 12-month-old G2019S KI mice [92]. We cannot easily explain this difference since both strains of G2019S KI mice are backcrossed on C57BL and bear similar kinase-enhancing mutations on exon 41 [29, 92]. Indeed, kinase activity appears to be elevated in both strains, as evaluated by in vitro kinase assays on synthetic substrates [29, 92]. We confirmed this finding in vivo, showing that, in good agreement with previous work on brain lysates of BAC

G2019S mice [72], pSer1292 levels were ~8-fold higher in the striatum of G2019S KI mice compared to WT controls. pSer1292 appears a more reliable marker of kinase activity with respect to ATP γ-phosphate incorporation measured in in vitro assays. Indeed, Ser1292 LRRK2 is an autophosphorylation site, and pSer1292 levels correlate with in vivo kinase activity [72]. pSer1292 levels are a more reliable readout of in vivo LRRK2 kinase activity even compared to pSer935 levels, since LRRK2 is phosphorylated at Ser935 by other kinases [14, 20, 67]. The discrepancies between these two strains of G2019S KI mice might be explained by quantitative differences in kinase activity along with inter-individual genomic variability, motor tests used, or environmental conditions.

Despite the lack of changes of DA release, the levels and functions of proteins involved in DA synaptic load (DAT) and vesicular storage (VMAT2) were altered in 12-month-old G2019S KI mice. Strikingly, these changes were age-dependent, since they were not observed in 3-month-old animals, indicating these changes are elements of an orchestrated, progressive response relying




**Fig. 6** Age-dependent dysfunction of VMAT2 expression and function in G2019S knock-in (KI) mice. Motor activity in 12-month-old G2019S KI mice and wild-type (WT) littermates treated with reserpine (1 mg/kg, i.p.) or saline, and challenged in the bar (a), drag (b) and rotarod (c) tests, before (baseline) and after (24 and 48 h) drug administration. Motor performance was expressed as percentage of performance at baseline. Data are means  $\pm$  SEM of  $n = 14-15$  mice per group and were analyzed using conventional ANOVA followed by the Newman-Keuls test for multiple comparisons. # $p < 0.05$ , ## $p < 0.01$  significantly different from saline. Kinetic analysis of [ $^3$ H]-DA uptake in whole-brain vesicles and Western blotting of VMAT2 levels in the striata from 12-month-old (d-f) or 3-month-old (g-i) G2019S KI mice and WT littermates. In Western blotting, two different anti-VMAT2 antibodies were used, one commercially available (e, h; Sigma) and another developed by Miller lab (f, i) (see Methods). Data are expressed as mean  $\pm$  SEM of 4 mice (d-f), 3 mice (g) or 5 mice (h, i) per group, performed in duplicate. Statistical analysis was performed by the Student *t*-test, two-tailed for unpaired data. \*\* $p < 0.01$ , different from WT

on the interaction between a genetic factor (the G2019S mutation) and aging, i.e. the main risk factor in PD.

DAT was upregulated in G2019S KI mice, which might represent a vulnerability factors for DA neurons [56]. Indeed, DAT overexpression has been associated with an increase of oxidative stress and neuronal degeneration [50] likely because cytosolic DA accumulation causes the buildup of reactive oxygen species and quinones, generated by DA autoxidation [25, 77, 79]. Moreover, cytosolic DA is metabolized by monoamine oxidase A to DOPAL, which causes synaptic dysfunction and terminal loss acting via different mechanisms, including cross-linking with  $\alpha$ -syn [9]. Finally, environmental


toxins causing PD, such as the toxic metabolite of MPTP, MPP<sup>+</sup>, are taken up by DA neurons through DAT. In fact, the greater susceptibility of BAC hG2019S overexpressing mice to the parkinsonian toxin MPTP can be explained by DAT upregulation [32].

Quite paradoxically, the increase of DAT activity was associated with a blunted neurochemical and behavioral response to GBR-12783. This is consistent with microdialysis works reporting a 35–50% reduction of nomifensine-induced DA release in the striatum of KI mice constitutively expressing R1441G LRRK2 [39] or temporally expressing G2019S LRRK2 [93]. Previous studies in cells have shown that DAT expression levels



inversely correlate with the potency of DAT blockers [12], a phenomenon also observed for the serotonin transporter [65]. Membrane DAT is in equilibrium between oligomeric and monomeric forms, and it has been hypothesized that higher DAT expression leads to higher DAT oligomerization, and DAT oligomers have lower affinity for DAT blockers with respect to monomers [38].

In line with that found in G2019S overexpressing mice [41], G2019S KI mice showed reduced striatal VMAT2 levels. This reduction was robust and consistent with the two different antibodies, one of which validated in VMAT2<sup>+/-</sup> mice [15]. Reduction of VMAT2 is observed also in PD patients [55] and is pathogenic in PD. In fact, filling synaptic vesicles via VMAT2 is a way to keep cytosolic DA levels in a nontoxic range; accordingly,



VMAT2 deletion induces neurodegeneration [80] whereas VMAT2 overexpression protects DA neurons [10, 42]. However, despite VMAT2 reduction further enhanced the already higher DAT/VMAT2 ratio in nigrostriatal DA neurons, thus increasing their vulnerability [56], G2019S KI mice did not show overt neurodegeneration (up to 19-months at least) or even significantly enhanced levels of DOPAL-bound  $\alpha$ -syn, a marker of DA

cytotoxicity. This questions the physiological meaning of the 50% reduction of VMAT2 observed in the striatal homogenate of G2019S KI mice. Indeed, contrary to that expected from the Western blot data, an increase in tetraabenazine-sensitive vesicular DA uptake was measured in G2019S KI mice *in vitro*. Although we cannot rule out the possibility that such increase is compensatory in nature, the possibility that this discrepancy relies

on technical reasons should be considered. In fact, the reduction of VMAT2 levels measured in striatal homogenate might not faithfully reflect a reduction of active VMAT2 expressed on mature, release-prone synaptic vesicles. In fact, VMAT2 levels measured by Western blot encompass also VMAT2 contained in immature secretory vesicles trafficking from the soma to presynaptic vesicle membrane, or recycling from the plasma membrane [30]. Interestingly, Sonsalla and collaborators [30] proved a disparity between tetrabenazine binding measured in striatal homogenate and striatal synaptic vesicles at 24 h after MPTP, showing that, under certain conditions, tetrabenazine binding measured in striatal homogenate may not be representative of vesicular VMAT2. On the other hand, the major limitation of a whole-brain preparation of synaptic vesicles is heterogeneity. VMAT2 is present not only in striatal dopaminergic terminals but also in noradrenergic, serotonergic and histaminergic terminals in striatal and extrastriatal areas. Since there is no possibility to dissect out the contribution of the different populations of VMAT2-positive synaptic vesicles in this whole-brain preparation, we cannot prove that the observed increase of vesicle uptake is really due to VMAT2 expressed on striatal vesicles, or is the net result of all changes of VMAT2 activity in different nerve terminals and brain areas.

Nonetheless, in favor of the hypothesis that vesicular DA uptake might be increased rather than reduced in G2019S KI mice, G2019S KI mice were relatively more resistant than WT controls to the hypolocomotive action of 1 mg/Kg reserpine *in vivo*, which is opposite from that expected from DA depleted vesicles. We can speculate that the greater resistance to reserpine might be due to a greater competition for VMAT2 of reserpine and cytosolic DA (the increase in DAT activity and the reduced DA turnover might overwhelm the buffering capacity of VMAT2, thus causing an increase in cytosolic DA). Alternatively, we might speculate that synaptic vesicles in G2019S KI mice are more enriched in DA, although only a trend to an increase in extracellular DA levels or in the K<sup>+</sup>-induced DA release was observed in the G2019S LRRK2 carriers.

It is therefore plausible that VMAT2 uptake elevation compensates for the loss of VMAT2 protein and protects from cytosolic DA toxicity, even in the presence of upregulated DAT. Whether this adaptive change will be effective throughout the life-span of G2019S KI mice is unknown, since we have investigated G2019S KI mice up to 19 months. However, it is also possible that other compensatory mechanisms will come into play to preserve DA homeostasis and DA neuron integrity.

In this respect, one important finding of the present study is that pSer129  $\alpha$ -syn levels are elevated in the striatum of G2019S KI mice. Since this was not

paralleled by an elevation of total  $\alpha$ -syn levels, we concluded that G2019S LRRK2 facilitates this posttranslational modification of  $\alpha$ -syn. This is in line with a recent study showing that the formation of pSer129  $\alpha$ -syn-positive inclusions in nigral DA neurons in response to intranigral  $\alpha$ -syn fibrils injection is accelerated in BAC hG2019S rats [86]. pSer129  $\alpha$ -syn [24] is the predominant form of syn in Lewy bodies [1], and for this reason it has been hypothesized to favor  $\alpha$ -syn aggregation, thus contributing to PD [57]. However, the role of pSer129  $\alpha$ -syn phosphorylation in  $\alpha$ -syn toxicity *in vivo* is still under debate [57, 81]. In fact, from the published literature it appears that depending on which kinase is involved in Ser129  $\alpha$ -syn phosphorylation, either neurotoxicity (G protein receptor kinases) [11, 71] or neuroprotection (Polo-like kinase 2) [58] can ensue. Moreover, LRRK2, and more intensely G2019S LRRK2, can directly Ser129-phosphorylate  $\alpha$ -syn *in vitro* [63]. Pinning down the pathway underlying Ser129  $\alpha$ -syn phosphorylation might help understand whether this modification is protective or pathogenic for DA neurons.

## Conclusion

We previously reported that G2019S KI mice have enhanced motor performance starting at 6 months of age [43]. We now show that this behavior is not sustained by enhanced DA release, suggesting that other mechanisms, such amplified postsynaptic D1 receptor signaling [54, 61] or glutamate release [3], might contribute. Of note, this study reveals for the first time that G2019S KI mice progressively develop (between 3 and 12 months) dysfunctions of plasma membrane and vesicular DA transporters, along with an overload of pSer129  $\alpha$ -syn inclusions in striatum. These adaptive changes were not associated with overt nigro-striatal DA degeneration or changes of striatal DA release, indicating DA homeostasis is preserved, at least up to 19-months. Nonetheless, they might represent vulnerability factors to DA neurons. A more stringent analysis of the time-course of these changes might help elucidate how this response of DA terminals is orchestrated, and how these factors relate to each other and, ultimately, to G2019S LRRK2. In fact, there is no evidence that G2019S LRRK2 can directly affect DAT or VMAT2 trafficking, although this possibility is worth investigating due to the role of LRRK2 in endosome and autophagosome pathways [68]. Nonetheless, G2019S LRRK2 could do so indirectly, through pSer129  $\alpha$ -syn. Indeed,  $\alpha$ -syn stimulates DAT activity [23, 36] and G2019S LRRK2 has been shown to increase this property by phosphorylating  $\alpha$ -syn at Ser129 [27]. Preliminary evidence that  $\alpha$ -syn controls VMAT2 activity has also been collected in cells where  $\alpha$ -syn knockdown causes an increase and A53T  $\alpha$ -syn overexpression a reduction

[22, 44]: nonetheless, the role of the pSer129 remains unknown. Whatever the mechanistic interactions between these players are, the gradual development of this response offers a wide time-window for a pharmacological intervention (e.g. with LRRK2 inhibitors) that could establish the role of the kinase vs non kinase activities of LRRK2.

In conclusion, G2019S KI mice might represent a pre-symptomatic model of PD, a valuable tool to verify a “multi-hit” hypothesis of PD [78], where genetic variables (G2019S LRRK2), an established risk factor (aging), and internal (e.g. DA,  $\alpha$ -syn) or environmental (e.g. MPTP) factors interact to shape the emergence of the parkinsonian phenotype.

#### Acknowledgements

This work was supported by grants from the Telethon Foundation (#GGP12237 to M.M. and E.G.) and by the Italian Ministry of Health (#RF-2011-02349806 to M.M.). O.S.M. was funded by the Michael J. Fox Foundation for Parkinson's research (Dyskinesia Challenge 2013). R.T.K. is funded by NIH EB 003320. We thank Dr K Lohr and Dr GW Miller for donating the anti-VMAT2 antibody.

#### Authors' contribution

FL performed behavioral and microdialysis studies, run statistical analysis and drafted the manuscript. DM performed western blot and statistical analysis, behavioral and in vitro release studies and vesicle preparation. SN performed immunohistochemistry and behavioral analysis. LA performed immunohistochemistry analysis. AB performed behavioral and microdialysis studies. FV performed uptake studies and statistical analysis. IR and GB performed western blot and statistical analysis. OSM analysed neurotransmitter levels in dialysates. DRS provided G2019S KI mice and participated in the design of the study. RTK, KV, LB, EG participated in the design and coordination of the study. MM conceived and coordinated the study, and drafted the manuscript. All authors read and approved the final manuscript.

#### Competing interests

M. Morari has received grants from the Telethon Foundation and the Italian Ministry of Health, and honoraria for speaking at symposia. E. Greggio has received grants from the Telethon Foundation. R.T. Kennedy has received grants from the National Institute of Health, O.S. Mabrouk from the Michael J Fox Foundation. D.S. is an employee of Novartis Pharma AG. The other Authors declare that they have no competing interest.

#### Ethics approval

“All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.”

“All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted.”

#### Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

#### Author details

<sup>1</sup>Department of Medical Sciences, Section of Pharmacology, and National Institute of Neuroscience, University of Ferrara, via Fossato di Mortara 17-19, 44121 Ferrara, Italy. <sup>2</sup>Department of Biology, University of Padova, Via Ugo Bassi 58/B, 35131 Padova, Italy. <sup>3</sup>Departments of Pharmacology and Chemistry, University of Michigan, 930 North University, Ann Arbor, MI 48109, USA. <sup>4</sup>Department of Autoimmunity/Transplantation/ Inflammation-Neuroinflammation, Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4002 Basel, Switzerland.

Received: 26 January 2017 Accepted: 8 March 2017

Published online: 14 March 2017

#### References

- Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, Caccavello RJ, Barbour R, Huang J, Kling K, Lee M, Diep L, Keim PS, Shen X, Chataway T, Schlossmacher MG, Seubert P, Schenk D, Sinha S, Gai WP, Chilcote TJ (2006) Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. *J Biol Chem* 281:29739–29752. doi:10.1074/jbc.M600933200
- Arcuri L, Viaro R, Bido S, Longo F, Calcagno M, Fernagut PO, Zaveri NT, Calo G, Bezzard E, Morari M (2016) Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease. *Neurobiol Dis* 89:55–64. doi:10.1016/j.nbd.2016.01.016
- Beccano-Kelly DA, Kuhlmann N, Tatarnikov I, Volta M, Munsie LN, Chou P, Cao LP, Han H, Tapia L, Farrer MJ, Milnerwood AJ (2014) Synaptic function is modulated by LRRK2 and glutamate release is increased in cortical neurons of G2019S LRRK2 knock-in mice. *Front Cell Neurosci* 8:301. doi:10.3389/fncel.2014.00301
- Beccano-Kelly DA, Volta M, Munsie LN, Paschall SA, Tatarnikov I, Co K, Chou P, Cao LP, Bergeron S, Mitchell E, Han H, Melrose HL, Tapia L, Raymond LA, Farrer MJ, Milnerwood AJ (2015) LRRK2 overexpression alters glutamatergic presynaptic plasticity, striatal dopamine tone, postsynaptic signal transduction, motor activity and memory. *Hum Mol Genet* 24:1336–1349. doi:10.1093/hmg/ddu543
- Bezzard E (2003) Neuroprotection for Parkinson's disease: a call for clinically driven experimental design. *Lancet Neurol* 2:393
- Bido S, Marti M, Morari M (2011) Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels. *J Neurochem* 118:1043–1055. doi:10.1111/j.1471-4159.2011.07376.x
- Bourdenx M, Dovero S, Engeln M, Bido S, Bastide MF, Duthiel N, Vollenweider I, Baud L, Piron C, Grouthier V, Boraud T, Porras G, Li Q, Baekelandt V, Scheller D, Michel A, Fernagut PO, Georges F, Courtine G, Bezzard E, Dehay B (2015) Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by alpha-synuclein overexpression. *Acta Neuropathol Commun* 3:46. doi:10.1186/s40478-015-0222-2
- Burke WJ (2003) 3,4-dihydroxyphenylacetaldehyde: a potential target for neuroprotective therapy in Parkinson's disease. *Curr Drug Targets CNS Neurol Disord* 2:143–148
- Burke WJ, Kumar VB, Pandey N, Panneton WM, Gan Q, Franko MW, O'Dell M, Li SW, Pan Y, Chung HD, Galvin JE (2008) Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine. *Acta Neuropathol* 115:193–203. doi:10.1007/s00401-007-0303-9
- Caudle WM, Richardson JR, Wang MZ, Taylor TN, Guillot TS, McCormack AL, Colebrooke RE, Di Monte DA, Emson PC, Miller GW (2007) Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. *J Neurosci* 27:8138–8148. doi:10.1523/JNEUROSCI.0319-07.2007
- Chen L, Feany MB (2005) Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. *Nat Neurosci* 8:657–663. doi:10.1038/nm1443
- Chen N, Reith ME (2007) Substrates and inhibitors display different sensitivity to expression level of the dopamine transporter in heterologously expressing cells. *J Neurochem* 101:377–388. doi:10.1111/j.1471-4159.2006.04384.x
- Chen CY, Weng YH, Chien KY, Lin KJ, Yeh TH, Cheng YP, Lu CS, Wang HL (2012) G2019S LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD. *Cell Death Differ* 19:1623–1633. doi:10.1038/cdd.2012.42
- Chia R, Haddock S, Beilina A, Rudenko IN, Mamais A, Kaganovich A, Li Y, Kumaran R, Nalls MA, Cookson MR (2014) Phosphorylation of LRRK2 by casein kinase 1alpha regulates trans-Golgi clustering via differential interaction with ARHGAP7. *Nat Commun* 5:5827. doi:10.1038/ncomms6827
- Cliburn RA, Dunn AR, Stout KA, Hoffman CA, Lohr KM, Bernstein AI, Winokur EJ, Burkett J, Shmitz Y, Caudle WM, Miller GW (2016) Immunohistochemical localization of vesicular monoamine transporter 2 (VMAT2) in mouse brain. *J Chem Neuroanat*. doi:10.1016/j.jchemneu.2016.11.003
- Cookson MR (2010) The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. *Nat Rev Neurosci* 11:791–797. doi:10.1038/nrn2935
- Cookson MR (2015) LRRK2 Pathways Leading to Neurodegeneration. *Curr Neurol Neurosci Rep* 15:42. doi:10.1007/s11910-015-0564-y

18. Covy JP, Yuan W, Waxman EA, Hurtig HI, Van Deerlin VM, Giasson BI (2009) Clinical and pathological characteristics of patients with leucine-rich repeat kinase-2 mutations. *Mov Disord* 24:32–39. doi:10.1002/mds.22096
19. Dachsel JC, Farrer MJ (2010) LRRK2 and Parkinson disease. *Arch Neurol* 67:542–547. doi:10.1001/archneurol.2010.79
20. Dzamko N, Deak M, Hentati F, Reith AD, Prescott AR, Alessi DR, Nichols RJ (2010) Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization. *Biochem J* 430:405–413. doi:10.1042/BJ20100784
21. Follmer C, Coelho-Cerqueira E, Yatabe-Franco DY, Araujo GD, Pinheiro AS, Domont GB, Eliezer D (2015) Oligomerization and Membrane-binding Properties of Covalent Adducts Formed by the Interaction of alpha-Synuclein with the Toxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde (DOPAL). *J Biol Chem* 290:27660–27679. doi:10.1074/jbc.M115.686584
22. Fountaine TM, Venda LL, Warrick N, Christian HC, Brundin P, Channon KM, Wade-Martins R (2008) The effect of alpha-synuclein knockdown on MPP+ toxicity in models of human neurons. *Eur J Neurosci* 28:2459–2473. doi:10.1111/j.1460-9568.2008.06527.x
23. Fountaine TM, Wade-Martins R (2007) RNA interference-mediated knockdown of alpha-synuclein protects human dopaminergic neuroblastoma cells from MPP+ toxicity and reduces dopamine transport. *J Neurosci Res* 85:351–363. doi:10.1002/jnr.21125
24. Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwatsubo T (2002) alpha-Synuclein is phosphorylated in synucleinopathy lesions. *Nat Cell Biol* 4:160–164. doi:10.1038/ncb748
25. Goldstein DS, Sullivan P, Cooney A, Jinsmaa Y, Sullivan R, Gross DJ, Holmes C, Kopin IJ, Sharabi Y (2012) Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinson's disease. *J Neurochem* 123:932–943. doi:10.1111/j.1471-4159.2012.07924.x
26. Greggio E, Jain S, Kingsbury A, Bandopadhyay R, Lewis P, Kaganovich A, van der Brug MP, Beilina A, Blackinton J, Thomas KJ, Ahmad R, Miller DW, Kesavapany S, Singleton A, Lees A, Harvey RJ, Harvey K, Cookson MR (2006) Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. *Neurobiol Dis* 23:329–341. doi:10.1016/j.nbd.2006.04.001
27. Hara S, Arawaka S, Sato H, Machiya Y, Cui C, Sasaki A, Koyama S, Kato T (2013) Serine 129 phosphorylation of membrane-associated alpha-synuclein modulates dopamine transporter function in a G protein-coupled receptor kinase-dependent manner. *Mol Biol Cell* 24(1649-1660):S1641–1643. doi:10.1091/mbc.E12-12-0903
28. Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, Bressman S, Brice A, Aasly J, Zabetian CP, Goldwurm S, Ferreira JJ, Tolosa E, Kay DM, Klein C, Williams DR, Marras C, Lang AE, Wszolek ZK, Berciano J, Schapira AH, Lynch T, Bhatia KP, Gasser T, Lees AJ, Wood NW, International LC (2008) Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. *Lancet Neurol* 7:583–590. doi:10.1016/S1474-4422(08)70117-0
29. Herzig MC, Kolly C, Persohn E, Theil D, Schweizer T, Hafner T, Stemmelen C, Troxler TJ, Schmid P, Danner S, Schnell CR, Mueller M, Kinzel B, Grevot A, Bolognani F, Stirn M, Kuhn RR, Kaufmann K, van der Putten PH, Rovelli G, Shimshek DR (2011) LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. *Hum Mol Genet* 20:4209–4223. doi:10.1093/hmg/ddr348
30. Hogan KA, Staal RG, Sonsalla PK (2000) Analysis of VMAT2 binding after methamphetamine or MPTP treatment: disparity between homogenates and vesicle preparations. *J Neurochem* 74:2217–2220
31. Kalia LV, Lang AE, Hazrati LN, Fujioka S, Wszolek ZK, Dickson DW, Ross OA, Van Deerlin VM, Trojanowski JQ, Hurtig HI, Alcalay RN, Marder KS, Clark LN, Gaig C, Tolosa E, Ruiz-Martinez J, Marti-Masso JF, Ferrer I, Lopez de Munain A, Goldman SM, Schule B, Langston JW, Aasly JO, Giordana MT, Bonifati V, Puschmann A, Canesi M, Pezzoli G, Maues De Paula A, Hasegawa K, Duyckaerts C, Brice A, Stoessl AJ, Marras C (2015) Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. *JAMA Neurol* 72:100–105. doi:10.1001/jamaneurol.2014.2704
32. Karuppagounder SS, Xiong Y, Lee Y, Lawless MC, Kim D, Nordquist E, Martin I, Ge P, Brahmachari S, Jhaldiyal A, Kumar M, Andrabi SA, Dawson TM, Dawson VL (2016) LRRK2 G2019S transgenic mice display increased susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-mediated neurotoxicity. *J Chem Neuroanat*. doi:10.1016/j.jchemneu.2016.01.007
33. Khan NL, Jain S, Lynch JM, Pavese N, Abou-Sleiman P, Holton JL, Healy DG, Gilks WP, Sweeney MG, Ganguly M, Gibbons V, Gandhi S, Vaughan J, Eunson LH, Katzenschlager R, Gayton J, Lennox G, Revesz T, Nicholl D, Bhatia KP, Quinn N, Brooks D, Lees AJ, Davis MB, Piccini P, Singleton AB, Wood NW (2005) Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. *Brain* 128:2786–2796. doi:10.1093/brain/awh667
34. Larsen JO, Gundersen HJ, Nielsen J (1998) Global spatial sampling with isotropic virtual planes: estimators of length density and total length in thick, arbitrarily orientated sections. *J Microsc* 191:238–248
35. LaVoie MJ, Ostaszewski BL, Weihofen A, Schlossmacher MG, Selkoe DJ (2005) Dopamine covalently modifies and functionally inactivates parkin. *Nat Med* 11:1214–1221. doi:10.1038/nm1314
36. Lee FJ, Liu F, Pristupa ZB, Niznik HB (2001) Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. *FASEB J* 15:916–926
37. Lee JW, Tappas V, Di Maio R, Greenamyre JT, Cannon JR (2015) Behavioral, neurochemical, and pathologic alterations in bacterial artificial chromosome transgenic G2019S leucine-rich repeated kinase 2 rats. *Neurobiol Aging* 36:505–518. doi:10.1016/j.neurobiolaging.2014.07.011
38. Li Y, Cheng SY, Chen N, Reith ME (2010) Interrelation of dopamine transporter oligomerization and surface presence as studied with mutant transporter protein and amphetamine. *J Neurochem* 114:873–885. doi:10.1111/j.1471-4159.2010.06818.x
39. Li Y, Liu W, Oo TF, Wang L, Tang Y, Jackson-Lewis V, Zhou C, Geghman K, Bogdanov M, Przedborski S, Beal MF, Burke RE, Li C (2009) Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. *Nat Neurosci* 12:826–828. doi:10.1038/nn.2349
40. Li X, Patel JC, Wang J, Avshalomov MV, Nicholson C, Buxbaum JD, Elder GA, Rice ME, Yue Z (2010) Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. *J Neurosci* 30:1788–1797. doi:10.1523/JNEUROSCI.5604-09.2010
41. Liu G, Sgobio C, Gu X, Sun L, Lin X, Yu J, Parisiadou L, Xie C, Sastry N, Ding J, Lohr KM, Miller GW, Mateo Y, Lovinger DM, Cai H (2015) Selective expression of Parkinson's disease-related Leucine-rich repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression. *Hum Mol Genet* 24:5299–5312. doi:10.1093/hmg/ddv249
42. Lohr KM, Bernstein AI, Stout KA, Dunn AR, Lazo CR, Alter SP, Wang M, Li Y, Fan X, Hess EJ, Yi H, Vecchio LM, Goldstein DS, Guillot TS, Salahpour A, Miller GW (2014) Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo. *Proc Natl Acad Sci U S A* 111:9977–9982. doi:10.1073/pnas.1402134111
43. Longo F, Russo I, Shimshek DR, Greggio E, Morari M (2014) Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging. *Neurobiol Dis* 71:62–73. doi:10.1016/j.nbd.2014.07.013
44. Lotharius J, Theil D, Wiekop P, Lundberg C, Raymon HK, Brundin P (2002) Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line. *J Biol Chem* 277:38884–38894. doi:10.1074/jbc.M205518200
45. Mabrouk OS, Marti M, Morari M (2010) Endogenous nociceptin/orphanin FQ (N/OFQ) contributes to haloperidol-induced changes of nigral amino acid transmission and parkinsonism: a combined microdialysis and behavioral study in naive and nociceptin/orphanin FQ receptor knockout mice. *Neuroscience* 166:40–48. doi:10.1016/j.neuroscience.2009.12.006
46. Marras C, Alcalay RN, Caspell-Garcia C, Coffey C, Chan P, Duda JE, Facheris MF, Fernandez-Santiago R, Ruiz-Martinez J, Mestre T, Saunders-Pullman R, Pont-Sunyer C, Tolosa E, Waro B, Consortium LC (2016) Motor and nonmotor heterogeneity of LRRK2-related and idiopathic Parkinson's disease. *Mov Disord* 31:1192–1202. doi:10.1002/mds.26614
47. Marti M, Mela F, Fantin M, Zucchini S, Brown JM, Witte J, Di Benedetto M, Buzas B, Reinscheid RK, Salvadori S, Guerrini R, Romualdi P, Candelletti S, Simonato M, Cox BM, Morari M (2005) Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease. *J Neurosci* 25:9591–9601. doi:10.1523/JNEUROSCI.2546-05.2005
48. Marti M, Mela F, Ulazzi L, Hanau S, Stocchi S, Paganini F, Beani L, Bianchi C, Morari M (2003) Differential responsiveness of rat striatal nerve endings to

- the mitochondrial toxin 3-nitropropionic acid: implications for Huntington's disease. *Eur J Neurosci* 18:759–767
49. Martin I, Kim JW, Dawson VL, Dawson TM (2014) LRRK2 pathobiology in Parkinson's disease. *J Neurochem* 131:554–565. doi:10.1111/jnc.12949
  50. Masoud ST, Vecchio LM, Bergeron Y, Hossain MM, Nguyen LT, Bermejo MK, Kile B, Sotnikova TD, Siesser WB, Gainetdinov RR, Wightman RM, Caron MG, Richardson JR, Miller GW, Ramsey AJ, Cyr M, Salahpour A (2015) Increased expression of the dopamine transporter leads to loss of dopamine neurons, oxidative stress and L-DOPA reversible motor deficits. *Neurobiol Dis* 74:66–75. doi:10.1016/j.nbd.2014.10.016
  51. Mata IF, Wedemeyer WJ, Farrer MJ, Taylor JP, Gallo KA (2006) LRRK2 in Parkinson's disease: protein domains and functional insights. *Trends Neurosci* 29:286–293. doi:10.1016/j.tins.2006.03.006
  52. Mattamall MB, Haring JH, Chung HD, Raghu G, Strong R (1995) An endogenous dopaminergic neurotoxin: implication for Parkinson's disease. *Neurodegeneration* 4:271–281
  53. Melrose HL, Dachsel JC, Behrouz B, Lincoln SJ, Yue M, Hinkle KM, Kent CB, Korvatska E, Taylor JP, Witten L, Liang YQ, Beevers JE, Boules M, Dugger BN, Serna VA, Gaukhan A, Yu X, Castaneda-Casey M, Braithwaite AT, Ogholikhan S, Yu N, Bass D, Tyndall G, Schellenberg GD, Dickson DW, Janus C, Farrer MJ (2010) Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. *Neurobiol Dis* 40:503–517. doi:10.1016/j.nbd.2010.07.010
  54. Migheli R, Del Giudice MG, Spisus Y, Sanna G, Xiong Y, Dawson TM, Dawson VL, Galioto M, Rocchitta G, Biosa A, Serra PA, Carri MT, Crosio C, Iaccarino C (2013) LRRK2 affects vesicle trafficking, neurotransmitter extracellular level and membrane receptor localization. *PLoS One* 8:e77198. doi:10.1371/journal.pone.0077198
  55. Miller GW, Erickson JD, Perez JT, Penland SN, Mash DC, Rye DB, Levey AI (1999) Immunohistochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease. *Exp Neurol* 156:138–148. doi:10.1006/exnr.1998.7008
  56. Miller GW, Gainetdinov RR, Levey AI, Caron MG (1999) Dopamine transporters and neuronal injury. *Trends Pharmacol Sci* 20:424–429
  57. Oueslati A (2016) Implication of Alpha-Synuclein Phosphorylation at S129 in Synucleinopathies: What Have We Learned in the Last Decade? *J Parkinson's Dis* 6:39–51. doi:10.3233/JPD-160779
  58. Oueslati A, Schneider BL, Aebischer P, Lashuel HA (2013) Polo-like kinase 2 regulates selective autophagic alpha-synuclein clearance and suppresses its toxicity in vivo. *Proc Natl Acad Sci U S A* 110:E3945–3954. doi:10.1073/pnas.1309991110
  59. Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der Brug M, Lopez de Munain A, Aparicio S, Gil AM, Khan N, Johnson J, Martinez JR, Nicholl D, Carrera IM, Pena AS, de Silva R, Lees A, Marti-Masso JF, Perez-Tur J, Wood NW, Singleton AB (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. *Neuron* 44:595–600. doi:10.1016/j.neuron.2004.10.023
  60. Panneton WM, Kumar VB, Gan Q, Burke WJ, Galvin JE (2010) The neurotoxicity of DOPAL: behavioral and stereological evidence for its role in Parkinson disease pathogenesis. *PLoS One* 5:e15251. doi:10.1371/journal.pone.0015251
  61. Parisiadou L, Yu J, Sgobio C, Xie C, Liu G, Sun L, Gu XL, Lin X, Crowley NA, Lovinger DM, Cai H (2014) LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity. *Nat Neurosci* 17:367–376. doi:10.1038/nn.3636
  62. Paxinos G, Franklin KBJ (2001) The mouse brain in stereotaxic coordinates, 2nd edn. Academic, San Diego
  63. Qing H, Wong W, McGeer EG, McGeer PL (2009) Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications. *Biochem Biophys Res Commun* 387:149–152. doi:10.1016/j.bbrc.2009.06.142
  64. Ramonet D, Daher JP, Lin BM, Stafa K, Kim J, Banerjee R, Westerlund M, Pletnikova O, Glauser L, Yang L, Liu Y, Swing DA, Beal MF, Troncoso JC, McCaffery JM, Jenkins NA, Copeland NG, Galter D, Thomas B, Lee MK, Dawson TM, Dawson VL, Moore DJ (2011) Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. *PLoS One* 6:e18568. doi:10.1371/journal.pone.0018568
  65. Ramsey IS, DeFelice LJ (2002) Serotonin transporter function and pharmacology are sensitive to expression level: evidence for an endogenous regulatory factor. *J Biol Chem* 277:14475–14482. doi:10.1074/jbc.M110783200
  66. Rees JN, Florang VR, Eckert LL, Doorn JA (2009) Protein reactivity of 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite, is dependent on both the aldehyde and the catechol. *Chem Res Toxicol* 22:1256–1263. doi:10.1021/tx9000557
  67. Reynolds A, Doggett EA, Riddle SM, Lebakken CS, Nichols RJ (2014) LRRK2 kinase activity and biology are not uniformly predicted by its autophosphorylation and cellular phosphorylation site status. *Front Mol Neurosci* 7:54. doi:10.3389/fnmol.2014.00054
  68. Roosen DA, Cookson MR (2016) LRRK2 at the interface of autophagosomes, endosomes and lysosomes. *Mol Neurodegener* 11:73. doi:10.1186/s13024-016-0140-1
  69. Saito Y, Kawashima A, Ruberu NN, Fujiwara H, Koyama S, Sawabe M, Arai T, Nagura H, Yamanouchi H, Hasegawa M, Iwatsubo T, Murayama S (2003) Accumulation of phosphorylated alpha-synuclein in aging human brain. *J Neuropathol Exp Neurol* 62:644–654
  70. Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, Kubo M, Kawaguchi T, Tsunoda T, Watanabe M, Takeda A, Tomiyama H, Nakashima K, Hasegawa K, Obata F, Yoshikawa T, Kawakami H, Sakoda S, Yamamoto M, Hattori N, Murata M, Nakamura Y, Toda T (2009) Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. *Nat Genet* 41:1303–1307. doi:10.1038/ng.485
  71. Sato H, Arawaka S, Hara S, Fukushima S, Koga K, Koyama S, Kato T (2011) Authentically phosphorylated alpha-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease. *J Neurosci* 31:16884–16894. doi:10.1523/JNEUROSCI.3967-11.2011
  72. Sheng Z, Zhang S, Bustos D, Kleinheinz T, Le Pichon CE, Dominguez SL, Solanoy HO, Drummond J, Zhang X, Ding X, Cai F, Song Q, Li X, Yue Z, van der Brug MP, Burdick DJ, Gunzner-Toste J, Chen H, Liu X, Estrada AA, Sweeney ZK, Searce-Levie K, Moffat JG, Kirkpatrick DS, Zhu H (2012) Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations. *Sci Transl Med* 4:164ra161. doi:10.1126/scitranslmed.3004485
  73. Singleton AB, Farrer MJ, Bonifati V (2013) The genetics of Parkinson's disease: progress and therapeutic implications. *Mov Disord* 28:14–23. doi:10.1002/mds.25249
  74. Sloan M, Alegre-Abarrategui J, Potgieter D, Kaufmann AK, Exley R, Deltheil T, Threlfell S, Connor-Robson N, Brimblecombe K, Wallings R, Cioroch M, Bannerman DM, Bolam JP, Magill PJ, Cragg SJ, Dodson PD, Wade-Martins R (2016) LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function. *Hum Mol Genet* 25:951–963. doi:10.1093/hmg/ddv628
  75. Song P, Mabrouk OS, Hershey ND, Kennedy RT (2012) In vivo neurochemical monitoring using benzoyl chloride derivatization and liquid chromatography-mass spectrometry. *Anal Chem* 84:412–419. doi:10.1021/ac202794q
  76. Steger M, Tonelli F, Ito G, Davies P, Trost M, Vetter M, Wachter S, Lorentzen E, Duddy G, Wilson S, Baptista MA, Fiske BK, Fell MJ, Morrow JA, Reith AD, Alessi DR, Mann M (2016) Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases. *Elife* 5. doi:10.7554/eLife.12813
  77. Stokes AH, Hastings TG, Vrana KE (1999) Cytotoxic and genotoxic potential of dopamine. *J Neurosci Res* 55:659–665. doi:10.1002/(SICI)1097-4547(19990315)55:6<659::AID-JNR1>3.0.CO;2-C
  78. Sulzer D (2007) Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. *Trends Neurosci* 30:244–250. doi:10.1016/j.tins.2007.03.009
  79. Sulzer D, Zecca L (2000) Intraneuronal dopamine-quinone synthesis: a review. *Neurotox Res* 1:181–195
  80. Taylor TN, Caudle WM, Miller GW (2011) VMAT2-Deficient Mice Display Nigral and Extranigral Pathology and Motor and Nonmotor Symptoms of Parkinson's Disease. *Parkinsons Dis* 2011:124165. doi:10.4061/2011/124165
  81. Tenreiro S, Eckermann K, Outeiro TF (2014) Protein phosphorylation in neurodegeneration: friend or foe? *Front Mol Neurosci* 7:42. doi:10.3389/fnmol.2014.00042
  82. Tong Y, Pisani A, Martella G, Karouani M, Yamaguchi H, Pothos EN, Shen J (2009) R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. *Proc Natl Acad Sci U S A* 106:14622–14627. doi:10.1073/pnas.0906334106
  83. Tsika E, Kannan M, Foo CS, Dikeman D, Glauser L, Gellhaar S, Galter D, Knott GW, Dawson TM, Dawson VL, Moore DJ (2014) Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic



- neurons of mice causes nuclear abnormalities without neurodegeneration. *Neurobiol Dis* 71:345–358. doi:10.1016/j.nbd.2014.08.027
84. Viaro R, Calcagno M, Marti M, Borrelli E, Morari M (2013) Pharmacological and genetic evidence for pre- and postsynaptic D2 receptor involvement in motor responses to nociceptin/orphanin FQ receptor ligands. *Neuropharmacology* 72:126–138. doi:10.1016/j.neuropharm.2013.04.046
  85. Viaro R, Sanchez-Pernaute R, Marti M, Trapella C, Isacson O, Morari M (2008) Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism. *Neurobiol Dis* 30:430–438. doi:10.1016/j.nbd.2008.02.011
  86. Volpicelli-Daley LA, Abdelmotilib H, Liu Z, Stoyka L, Daher JP, Milnerwood AJ, Unni VK, Hirst WD, Yue Z, Zhao HT, Fraser K, Kennedy RE, West AB (2016) G2019S-LRRK2 Expression Augments alpha-Synuclein Sequestration into Inclusions in Neurons. *J Neurosci* 36:7415–7427. doi:10.1523/JNEUROSCI.3642-15.2016
  87. Volta M, Mabrouk OS, Bido S, Marti M, Morari M (2010) Further evidence for an involvement of nociceptin/orphanin FQ in the pathophysiology of Parkinson's disease: a behavioral and neurochemical study in reserpinized mice. *J Neurochem* 115:1543–1555. doi:10.1111/j.1471-4159.2010.07061.x
  88. Weng YH, Chen CY, Lin KJ, Chen YL, Yeh TH, Hsiao IT, Chen IJ, Lu CS, Wang HL (2016) (R1441C) LRRK2 induces the degeneration of SN dopaminergic neurons and alters the expression of genes regulating neuronal survival in a transgenic mouse model. *Exp Neurol* 275 Pt 1:104–115. doi:10.1016/j.expneurol.2015.09.001
  89. Werner-Allen JW, DuMond JF, Levine RL, Bax A (2016) Toxic Dopamine Metabolite DOPAL Forms an Unexpected Dicatechol Pyrrole Adduct with Lysines of alpha-Synuclein. *Angew Chem Int Ed Engl* 55:7374–7378. doi:10.1002/anie.201600277
  90. West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, Ross CA, Dawson VL, Dawson TM (2005) Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. *Proc Natl Acad Sci U S A* 102:16842–16847. doi:10.1073/pnas.0507360102
  91. Yao C, El Khoury R, Wang W, Byrd TA, Pehek EA, Thacker C, Zhu X, Smith MA, Wilson-Delfosse AL, Chen SG (2010) LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a *Caenorhabditis elegans* model of Parkinson's disease. *Neurobiol Dis* 40:73–81. doi:10.1016/j.nbd.2010.04.002
  92. Yue M, Hinkle KM, Davies P, Trushina E, Fiesel FC, Christenson TA, Schroeder AS, Zhang L, Bowles E, Behrouz B, Lincoln SJ, Beevers JE, Milnerwood AJ, Kurti A, McLean PJ, Fryer JD, Springer W, Dickson DW, Farrer MJ, Melrose HL (2015) Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice. *Neurobiol Dis* 78:172–195. doi:10.1016/j.nbd.2015.02.031
  93. Zhou H, Huang C, Tong J, Hong WC, Liu YJ, Xia XG (2011) Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake. *Int J Biol Sci* 7:753–761
  94. Zhu J, Apparsundaram S, Dwoskin LP (2009) Nicotinic receptor activation increases [3H]dopamine uptake and cell surface expression of dopamine transporters in rat prefrontal cortex. *J Pharmacol Exp Ther* 328:931–939. doi:10.1124/jpet.108.147025
  95. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, Muller-Myhsok B, Dickson DW, Meitinger T, Strom TM, Wszolek ZK, Gasser T (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. *Neuron* 44:601–607. doi:10.1016/j.neuron.2004.11.005

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

